Jesús
San Miguel Izquierdo
Consultor Investigador
University of British Columbia
Vancouver, CanadáPublicaciones en colaboración con investigadores/as de University of British Columbia (5)
2020
-
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
Blood Cancer Journal, Vol. 10, Núm. 11
2018
-
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalanprednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
Haematologica, Vol. 103, Núm. 9, pp. 1518-1526
-
Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of POLLUX
Haematologica, Vol. 103, Núm. 12, pp. 2088-2096